RBR-3fwgnj招募中未知
Evaluation of angiogenic and antiangiogenic factors for differential diagnosis of preeclampsia and systemic lupus erythematosus with nephritis
niversidade do Estado do Rio de Janeiro - Faculdade de Ciências Médicas0 个研究点开始时间: 2019年11月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16Y 至 45Y（—）
- 性别
- Female
入选标准
- •Pregnant patients diagnosed with systemic lupus erythematosus between will be sequentially enrolled upon prenatal admission.
排除标准
- •Patients who do not wish to participate in the study; multiple pregnancies; pregnancies that are interrupted before 20 weeks.
研究者
相似试验
招募中
不适用
Analysis of Biomarkers From Patients With Chorioretinal DiseasesDiabetic RetinopathyMacular DegenerationNCT02026843Kyungpook National University Hospital100
进行中（未招募）
不适用
Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within theSwedish Association of Breast Oncologists SABO-2010-01Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC) can also be included. Patients with TNBC will not receive endocrine therapy.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022065-10-SESahlgrenska University Hospital
进行中（未招募）
不适用
Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later-Line Treatment in Patients with Advanced Non-Small Cell Lung CancerSecond-or Later Line treatment in patients with advanced Non-Small Cell lung CancerMedDRA version: 5.1Level: LLTClassification code 10061873EUCTR2005-003501-90-DEPfizer Pharma GmbH60
已完成
不适用
Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC)chronic central serous chorioretinopathyJPRN-UMIN000014110Kansai medical university takii hospital10
进行中（未招募）
不适用
A PIVOTAL PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736IN PATIENTS WITH 131I-REFRACTORY METASTATIC OR UNRESECTABLELOCALLY-ADVANCED PAPILLARY, FOLLICULAR, OR HURTHLE-CELL THYROID CANCER WHO ARE ALSO REFRACTORY TO, OR INTOLERANT OF,OR HAVE CLINICAL CONTRAINDICATION TO, DOXORUBICIN TREATMENT - NDTreatment of patients with 131I-refractory metastatic or unresectable locally-advancedpapillary, follicular, or Hurthle-cell thyroid cancer who are also refractory to, or intolerant of,or have clinical contraindication to, doxorubicin treatment.MedDRA version: 9.1Level: LLTClassification code 10055107Term: Thyroid cancer metastaticEUCTR2006-002576-18-ITPFIZER100